Last reviewed · How we verify
Striatin
Striatin is a Small molecule drug developed by Universitas Sriwijaya. It is currently in Phase 3 development. Also known as: Inbumin Forte.
Striatin is a small molecule used in clinical trials to study its efficacy in treating various conditions, including severe acute malnutrition and hypertension. It has been studied in combination with other compounds, such as Galatonol, in trials focused on malnourished children and weight gain.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Striatin |
|---|---|
| Also known as | Inbumin Forte |
| Sponsor | Universitas Sriwijaya |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Supplementation of Galatonol 300 mg / Striatin 30 mg in Postpartum Lactating Mothers (PHASE3)
- Efficacy of Striatin in Malnourished Children (PHASE3)
- Effects of Channa Striata Extract on Intestinal Inflammation and Nutritional Status in Malnutritional Toddlers After Albendazole Therapy in South Bangka District (NA)
- Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Striatin CI brief — competitive landscape report
- Striatin updates RSS · CI watch RSS
- Universitas Sriwijaya portfolio CI
Frequently asked questions about Striatin
What is Striatin?
Who makes Striatin?
Is Striatin also known as anything else?
What development phase is Striatin in?
Related
- Manufacturer: Universitas Sriwijaya — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Inbumin Forte
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing